Across business services, consumer & retail, energy, FIG, healthcare, industrials, real estate, tech-enabled services and TMT, the themes struck by our expert panel are consistent: AI, infrastructure and specialization. Kenny Walker-Durrant, partner in Technology and Life Sciences at Goodwin, says, "We expect big pharma to look to offload and spin-out early-stage assets or non-core assets so they can direct their efforts and cash on their late-stage assets that are more ready to fill their pipelines and generate revenue. They can still profit from their equity stakes, milestone payments and royalties if the spin-out succeeds. Future deals will come in all shapes and sizes."
Read the Mergers & Acquisitions article for more.